Exact Mass: 637.1828794

Exact Mass Matches: 637.1828794

Found 36 metabolites which its exact mass value is equals to given mass value 637.1828794, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Anacetrapib

5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4-fluoro-2-methoxy-5-(propan-2-yl)-4-(trifluoromethyl)-[1,1-biphenyl]-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one

C30H25F10NO3 (637.1674659999999)

{4-[2-Acetylamino-2-(1-biphenyl-4-ylmethyl-2-oxo-azepan-3-ylcarbamoyl)-ethyl]-2-phosphono-phenoxy}-acetic acid

2-[4-(2-{[1-({[1,1-biphenyl]-4-yl}methyl)-2-oxoazepan-3-yl]-C-hydroxycarbonimidoyl}-2-[(1-hydroxyethylidene)amino]ethyl)-2-phosphonophenoxy]acetate

C32H36N3O9P (637.2189056)

Chrymutasin B

C32H31NO13 (637.1795316)

Pelargonidin 3-(6-acetylglucoside)-5-glucoside

C29H33O16 (637.1768518)

Pelargonidin 3-glucoside-5-(6-acetylglucoside)

5- [ (6-O-Acetyl-beta-D-glucopyranosyl) oxy ] -3- (beta-D-glucopyranosyloxy) -4,7-dihydroxyflavylium

C29H33O16 (637.1768518)

Cyanidin 3-(4-acetylrutinoside)

C29H33O16 (637.1768518)

Luteolinidin 5-(3-glucoside-2-acetylglucoside)

5,7,3,4-Tetrahydroxyflavylium 5- (3-glucoside-2-acetylglucoside)

C29H33O16 (637.1768518)

Cyanidin-3-(2-acetylrutinoside)

3,5,7,3,4-Pentahydroxyflavylium 3- (2-acetylrutinoside)

C29H33O16 (637.1768518)

D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent D000890 - Anti-Infective Agents > D023303 - Oxazolidinones D009676 - Noxae > D000963 - Antimetabolites C471 - Enzyme Inhibitor

[(2S,4R,6S)-5-(1,3-dioxoisoindol-2-yl)-6-(4-methoxyphenoxy)-4-phenylmethoxy-2-(phenylmethoxymethyl)oxan-3-yl] acetate

C37H35NO9 (637.23117)

2,3,4,6-tetra-o-benzoyl-beta-d-glucopyranosyl isothiocyanate

C35H27NO9S (637.1406452000001)

3-(7-Bromo-9,9-diphenyl-9H-fluoren-2-yl)-9-phenyl-9H-carbazole

C43H28BrN (637.1404987999999)

2-Oxazolidinone, 5-[3,5-bis(trifluoromethyl)phenyl]-3-[[4-fluoro-2-methoxy-5-(1-methylethyl)-4-(trifluoromethyl)[1,1-biphenyl]-2-yl]methyl]-4-methyl-, (4S,5R)-

C30H25F10NO3 (637.1674659999999)

D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D000890 - Anti-Infective Agents > D023303 - Oxazolidinones D009676 - Noxae > D000963 - Antimetabolites

{4-[2-Acetylamino-2-(1-biphenyl-4-ylmethyl-2-oxo-azepan-3-ylcarbamoyl)-ethyl]-2-phosphono-phenoxy}-acetic acid

C32H36N3O9P (637.2189056)

CMP-N,N-diacetyllegionaminate(2-)

C22H32N5O15P-2 (637.1632452)

CMP-pseudaminate

C22H32N5O15P-2 (637.1632452)

CMP-diacetamido-8-epilegionaminic acid

C22H32N5O15P-2 (637.1632452)

2-[4-[2-Acetamido-3-oxo-3-[[2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]-2-phosphonophenoxy]acetic acid

C32H36N3O9P (637.2189056)

[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-[4-(4-chlorophenyl)-3-cyano-2-oxo-6-pyridin-2-ylpyridin-1-yl]oxan-2-yl]methyl acetate

C31H28ClN3O10 (637.1463138)

Cyanidin-3-(2-acetylrutinoside)

C29H33O16+ (637.1768518)

Akt1-IN-1

C31H32FN5O5S2 (637.1828794)

Akt1-IN-1 (compound 5b) is a potent and selective Akt1 inhibitor with an IC50 value of 18.79 nM in MIA Paca-2 cells. Akt1-IN-1 does not exhibit obvious teratogenicity, hepatotoxicity and cardiotoxicity (No Observed Adverse Effect Level > 100 μM). Akt1-IN-1 can be used for researching anticancer[1].

Cyanidin-3-(2'-acetylrutinoside)

Cyanidin 3-(2'-acetylrutinoside)

C29H33O16 (637.1768518)

Cyanidin 3-(4'-acetylrutinoside)

C29H33O16 (637.1768518)

Pelargonidin 3-(6'-acetylglucoside)-5-glucoside

C29H33O16 (637.1768518)

Pelargonidin 3-glucoside-5-(6'-acetylglucoside)

C29H33O16 (637.1768518)

10-amino-3-{[(2s,3r,4s,5r,6s)-4,5-dihydroxy-6-methyl-3-{[(2r,4s,5r,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-15-methyl-18-oxapentacyclo[10.6.2.0²,⁷.0⁹,¹⁹.0¹⁶,²⁰]icosa-1(19),2(7),3,5,9,12,14,16(20)-octaene-8,11,17-trione

10-amino-3-{[(2s,3r,4s,5r,6s)-4,5-dihydroxy-6-methyl-3-{[(2r,4s,5r,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-15-methyl-18-oxapentacyclo[10.6.2.0²,⁷.0⁹,¹⁹.0¹⁶,²⁰]icosa-1(19),2(7),3,5,9,12,14,16(20)-octaene-8,11,17-trione

C32H31NO13 (637.1795316)

10-amino-3-{[(2s,3r,4s,5r,6s)-4,5-dihydroxy-6-methyl-3-{[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-15-methyl-18-oxapentacyclo[10.6.2.0²,⁷.0⁹,¹⁹.0¹⁶,²⁰]icosa-1(19),2(7),3,5,9,12,14,16(20)-octaene-8,11,17-trione

10-amino-3-{[(2s,3r,4s,5r,6s)-4,5-dihydroxy-6-methyl-3-{[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-15-methyl-18-oxapentacyclo[10.6.2.0²,⁷.0⁹,¹⁹.0¹⁶,²⁰]icosa-1(19),2(7),3,5,9,12,14,16(20)-octaene-8,11,17-trione

C32H31NO13 (637.1795316)

(2s)-2-carboxy-5-{[(2s,3r,4s,5s,6r)-6-{[(2-carboxyacetyl)oxy]methyl}-3,4,5-trihydroxyoxan-2-yl]oxy}-1-{2-[(2s)-2,6-dicarboxy-2,3-dihydro-1h-pyridin-4-ylidene]ethylidene}-6-hydroxy-2,3-dihydro-1h-1λ⁵-indol-1-ylium

(2s)-2-carboxy-5-{[(2s,3r,4s,5s,6r)-6-{[(2-carboxyacetyl)oxy]methyl}-3,4,5-trihydroxyoxan-2-yl]oxy}-1-{2-[(2s)-2,6-dicarboxy-2,3-dihydro-1h-pyridin-4-ylidene]ethylidene}-6-hydroxy-2,3-dihydro-1h-1λ⁵-indol-1-ylium

[C27H29N2O16]+ (637.1517014)

10-amino-3-({4,5-dihydroxy-6-methyl-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl}oxy)-15-methyl-18-oxapentacyclo[10.6.2.0²,⁷.0⁹,¹⁹.0¹⁶,²⁰]icosa-1(19),2(7),3,5,9,12,14,16(20)-octaene-8,11,17-trione

10-amino-3-({4,5-dihydroxy-6-methyl-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl}oxy)-15-methyl-18-oxapentacyclo[10.6.2.0²,⁷.0⁹,¹⁹.0¹⁶,²⁰]icosa-1(19),2(7),3,5,9,12,14,16(20)-octaene-8,11,17-trione

C32H31NO13 (637.1795316)

5-{[(2s,3s,4s,5s,6r)-6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl]oxy}-7-hydroxy-2-(4-hydroxyphenyl)-3-{[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1λ⁴-chromen-1-ylium

[C29H33O16]+ (637.1768518)

2-(1-carboxy-n-{4-[(2s)-2-(carboxyamino)-2-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}-c-hydroxycarbonimidoyl)ethyl]phenyl}formamido)benzoic acid

C31H31N3O12 (637.1907646)

5-{[(2s,3r,4s,5r,6r)-3-(acetyloxy)-5-hydroxy-6-(hydroxymethyl)-4-{[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2-(3,4-dihydroxyphenyl)-7-hydroxy-1λ⁴-chromen-1-ylium

5-{[(2s,3r,4s,5r,6r)-3-(acetyloxy)-5-hydroxy-6-(hydroxymethyl)-4-{[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2-(3,4-dihydroxyphenyl)-7-hydroxy-1λ⁴-chromen-1-ylium

[C29H33O16]+ (637.1768518)

10-amino-3-{[(2s,3r,4s,5r,6r)-4,5-dihydroxy-6-methyl-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-15-methyl-18-oxapentacyclo[10.6.2.0²,⁷.0⁹,¹⁹.0¹⁶,²⁰]icosa-1(19),2(7),3,5,9,12,14,16(20)-octaene-8,11,17-trione

10-amino-3-{[(2s,3r,4s,5r,6r)-4,5-dihydroxy-6-methyl-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-15-methyl-18-oxapentacyclo[10.6.2.0²,⁷.0⁹,¹⁹.0¹⁶,²⁰]icosa-1(19),2(7),3,5,9,12,14,16(20)-octaene-8,11,17-trione

C32H31NO13 (637.1795316)

3-{[(2s,3r,4s,5s,6r)-6-({[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-5h-chromen-5-yl

C29H33O16 (637.1768518)